Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HanBio Therapeutics
Chinese Biotechs Feel Chill Wind Of Hesitant Investors
Large or small, Chinese biotechs are receiving the cold shoulder from some investors amid souring investment sentiment. HanBio, Frontier and InnoCare have all seen their fundraising efforts hampered to various degrees.
Finance Watch: Days Of Reckoning As Biopharma Valuations, Fundraising Opportunities Fluctuate
Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.